Surprisingly, high expression of RASSF1 and DAB2 predicted poor survival in the TCGA-HCC dataset (Supplementary Table S2), instead of a better prognosis expected of their function as negative regulators of the RAS-MAPK pathway. This evidence concerns the gene RASSF1 and hepatocellular carcinoma.